Mesoblast Limited (MESO)
MESO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1345099/000134509926000081/0001345099-26-000081-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2026-06-30.
Profile
| Field | Value |
|---|---|
| Ticker | MESO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Australia |
| IPO year | 2015 |
| SEC CIK | 0001345099 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | Australia |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $120.3M |
| Net income | -$57.5M |
| Operating income | Not in SEC XBRL data |
| Net margin | -47.8% |
| Operating margin | Operating income not reported |
| Revenue growth | +599.2% |
| Cash | $102.9M |
| Total assets | $773.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 13.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-08-27 |
| Cash and burn | $102.9M cash; operating cash flow -$11.0M a quarter. | Report 2026-06-30 |
| Shares outstanding | 129,686,278 (2026-06-30); 127,996,719 a year earlier; 81,420,483 three years earlier. 3y figure adjusted for split (1-for-2 overall). | Cover page 2026-06-30 |
| Reverse splits, 3 years | 1; latest 1-for-2 on 2024-01-10 | Source 2024-01-10 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2025-12-31 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers, Melbourne, Australia | PCAOB Form AP 2026-09-14 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $19.6M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2026 2026-06-30 | $120.3M | -$57.5M | -$43.8M | $102.9M | $119.2M | $120.3M | 20-F 2026-08-27 |
| FY 2025 2025-06-30 | $17.2M | -$102.1M | -$50.0M | $161.6M | $121.9M | $17.2M | 20-F 2025-08-29 |
| FY 2024 2024-06-30 | $5.9M | -$88.0M | -$48.5M | $63.0M | $114.3M | $5.9M | 20-F 2025-08-29 |
| FY 2023 2023-06-30 | $7.5M | -$81.9M | -$63.3M | $71.3M | $108.8M | $7.5M | 20-F 2025-08-29 |
| FY 2022 2022-06-30 | $10.2M | -$91.3M | -$65.8M | $60.4M | $101.7M | $10.2M | 20-F 2024-08-29 |
| FY 2021 2021-06-30 | $7.4M | -$98.8M | -$100.7M | $136.9M | $147.4M | $7.4M | 20-F 2023-08-31 |
| FY 2020 2020-06-30 | $32.2M | -$77.9M | -$50.4M | $129.3M | $89.5M | $32.2M | 20-F 2022-08-31 |
| FY 2019 2019-06-30 | $16.7M | -$89.8M | -$57.8M | $50.4M | $81.3M | $16.7M | 20-F 2021-08-31 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B3 | 2026-01-14 |
| Latest annual report | 20-F | 2026-08-27 |
| Latest quarterly / interim | 6-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 600 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -7.0% |
| 1 month | -4.5% |
| 3 months | -19.5% |
| Year to date | -26.4% |
| 1 year | -11.1% |
| From 52-week high | -36.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VIR | Vir Biotechnology Inc. | $9.58 | -3.82% | $1.6B |
| ALVO | Alvotech | $4.41 | +5.13% | $1.7B |
| WWB | Windward Bio Group AG Common Shares | $30.04 | +5.40% | $1.7B |
| IMCR | Immunocore Holdings plc | $28.88 | -3.54% | $1.5B |
| LYCA | Lycia Therapeutics Inc. | $28.61 | -8.30% | $1.5B |
| RXRX | Recursion Pharmaceuticals Inc. | $2.90 | -8.79% | $1.8B |
| COAG | Hemab Therapeutics Holdings Inc. | $39.05 | -4.42% | $1.8B |
| MAZE | Maze Therapeutics Inc. | $33.90 | -1.25% | $1.9B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier